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Abstract
Development of sensitive and specific biomarkers, preferably those circulating in body fluids is
critical for early diagnosis of cancer. This study performed profiling of microRNAs (miRNAs) in
exocrine pancreatic secretions (pancreatic juice) by microarray analysis utilizing pancreatic juice
from 6 pancreatic ductal adenocarcinoma (PDAC) patients and two pooled samples from 6
non-pancreatic, non-healthy (NPNH) as controls. Differentially circulating miRNAs were subsequently validated in 88 pancreatic juice samples from 50 PDAC, 19 chronic pancreatitis (CP) patients and 19 NPNH controls. A marked difference in the profiles of four circulating miRNAs
(miR-205, miR-210, miR-492, and miR-1427) was observed in pancreatic juice collected from patients with PDAC and those without pancreatic disease. Elevated levels of the four miRNAs together predicted PDAC with a specificity of 88% and sensitivity of 87%. Inclusion of serum CA19-9
level increased the sensitivity to 91% and the specificity to 100%. Enrichment of the four miRNAs
in pancreatic juice was associated with decreased OS, as was the combination of miR-205 and
miR-210. Higher contents of miR-205 and miR-210 were also associated with lymph node metastasis. Elevated levels of circulating miR-205, miR-210, miR-492, and miR-1247 in pancreatic juice
are, therefore, promising candidate biomarkers of disease and poor prognosis in patients with
PDAC.
Key words: miRNA; circulating; biomarker; pancreatic juice; pancreatic cancer.

Introduction
Pancreatic cancer is the fourth leading cause of
cancer-related deaths in the United States, with a
5-year survival rate of about 6% (1). When the tumor
is detected at an early stage, surgical resection and
adjuvant chemotherapy or radiotherapy can increase

the 5-year survival rate to 15-40% (2). Thus, screening
strategies for detection of early stage cancer or precursor lesions in individuals at highest risk, as well as
pancreatic cancer biomarker assays for biological
fluids, are urgently needed to reduce the high morhttp://www.jcancer.org
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bidity and mortality associated with this malignancy.
Exocrine pancreatic secretions, or pancreatic
juice, collected from the second part of the duodenum
after stimulation with intravenous synthetic human
secretin using an upper endoscope (3-5) have been
analyzed for molecular markers associated with pancreatic ductal adenocarcinoma (PDAC) (6, 7). Protein
and gene expression profiles in the pancreatic juice of
patients with PDAC have revealed novel protein
markers and indicator genes that might be useful for
PDAC diagnosis (8, 9). More recently, NGAL and
MIC-1 in pancreatic juice were reported to be useful
markers for diagnosing benign and malignant disease
of the pancreas (10). However, since tumor-associated
proteins may constitute only a minor fraction of the
vast and dynamic range of proteins in blood plasma
and other body fluids, proteomic-based strategies for
identification of circulating cancer biomarkers have
had limited success so far (11).
MicroRNAs (miRNAs) are a class of conserved
small non-coding RNAs, which regulate gene expression via complementarity with the 3'-untranslated
region of their target mRNAs, repressing translation
and causing degradation of multiple target mRNAs
(12). MicroRNAs have critical regulatory functions in
cell development, proliferation, differentiation,
apoptosis, and stress response. A number of studies in
the past few years have established the regulatory
roles of miRNAs in complex genetic networks underlying various cellular pathways (13). Aberrant
expression of several miRNAs has been detected in
PDAC and its precursor, pancreatic intraepithelial
neoplasm (14). Varying levels of circulating miRNAs
in body fluids have been associated with corresponding tumor-specific aberrant expression and
proposed to represent novel biomarkers for detection
and diagnosis of various cancers (15, 16). We have
earlier demonstrated that miRNAs in the plasma of
patients with pancreatic ductal adenocarcinoma
(PDAC) may serve as novel blood-based biomarkers
of disease (17). Serum and pancreatic cyst fluid levels
of miR-21, miR-210 and miR-155 have been found
elevated in patients with PDAC (18-21). Elevated serum level of miR-1290 has recently been reported to
accurately distinguish patients with low stage pancreatic cancer from healthy and disease controls (22).
Altered levels of miRNAs in blood and body
fluids can distinguish patients with cancer from
healthy individuals (16, 17, 23). In view of a published
report that relative expression levels of miR-21 and
miR-155 in tissue and pancreatic juice from PDAC
patients were significantly higher than those with
chronic pancreatitis (24), it appears that unbiased
profiling of circulating miRNAs in pancreatic juice
may offer a viable approach for developing reliable
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biomarker assays for detecting PDAC. In this study,
we performed microarray profiling of miRNAs in the
pancreatic juice of patients with PDAC compared
with those from individuals with chronic pancreatitis
and non-pancreatic disease controls to investigate the
utility of differentially circulating miRNAs as biomarkers for pancreatic cancer.

Materials and Methods
Patients
This prospective study was approved by the
Mayo Clinic and M. D. Anderson Cancer Center Institutional Review Boards. Patients presenting at the
Mayo Clinic with epigastric pain or discomfort warranting evaluation by endoscopic ultrasound-guided
fine needle aspiration and later diagnosed with
chronic pancreatitis (CP), pancreatic cancer or no
pancreatic disease (non-pancreatic, non-healthy
[NPNH] controls) were enrolled. Pancreatic juice and
serum samples were collected. Sera were assayed for
CA19-9 and the definitive final diagnosis was made. A
multiphase, case–control study was designed to identify pancreatic juice miRNAs as potential markers for
PDAC. In the initial biomarker identification stage,
miRNA microarray profiling was performed on six
pancreatic juice samples of PDAC patients and two
pooled pancreatic juice samples from 6 NPNH controls to assay the circulating miRNA profiles. Validation of four differentially enriched miRNAs was then
performed using qRT-PCR assay. All the pancreatic
juice samples were separated randomly into training
set (6 PDAC and 6 NPNH controls) and validation set
(44 PDAC, 19 CP and13 NPNH controls) prior to
analysis from a total of 88 patients enrolled in the
study as described previously (10).

Collection of Secretin-Stimulated Exocrine
Pancreatic Secretions (Pancreatic Juice)
All patients underwent upper endoscopic intubation after an overnight fast. Patients were moderately sedated with midazolam and meperidine before
the procedure. Synthetic human secretin (ChiRhoStim; ChiRhoClin Inc, Burtonsville, MD) at a dose of 0.2
μg/kg (or a total dose of 16 μg) was administered
intravenously for 1 minute immediately before endoscopic intubation. Gastric fluid was aspirated before
intubation of the pylorus to minimize contamination.
With the endoscope positioned in the second portion
of the duodenum, opposite the papilla of Vater
(without cannulation), a 2.3-mm plastic aspiration
catheter (Hobbs Medical, Stafford Springs, CT) was
passed through the biopsy channel of the endoscope
until it was visible on the endoscopic monitor screen.
Pancreatic juice exiting the papilla was then suctioned
http://www.jcancer.org
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through the catheter for 10 minutes into a dry 20-mL
tube attached to the proximal end of the catheter. On
average, 5-8 mL of fluid was collected from each patient. The collected fluid was immediately aliquoted
into 2-mL vials, snap-frozen in liquid nitrogen, and
stored at -80°C until assays for miRNA microarrays
and real-time polymerase chain reaction were performed. A pan-protease inhibitor cocktail pill (Roche
Diagnostic Corporation, Indianapolis, IN) was added
to the collected pancreatic juice to inhibit proteolytic
degradation.

Determination of Final Diagnosis
Three gastroenterologists (Massimo Raimondo,
Michael B. Wallace, and Timothy A. Woodward), who
were blinded to the results of the miRNA assays, determined the final diagnosis of the patients on the
basis of clinical history and laboratory, radiologic
(computed tomography or magnetic resonance imaging), or endoscopic (endoscopic ultrasound or endoscopic retrograde cholangiopancreatographic)
findings (chronic pancreatitis) and cytologic or histologic findings (for those with pancreatic ductal adenocarcinoma). Patients with no prior history of pancreatic disease and who had normal pancreatic test
results
(ultrasound,
cholangiopancreatography,
computed tomography, or magnetic resonance imaging) were deemed to have normal pancreata and thus
considered to be non-pancreatic, non-healthy (NPNH)
controls.

CA19-9 Measurement
Concentrations of CA19-9 in the pancreatic juice
and serum of patients were measured, as described
previously (10). Briefly, CA19-9 antigen concentration
was determined using a solid-phase radioimmunoassay (Centocor, Malvern, PA), according to the
manufacturer’s instructions. Quantities of CA19-9
were expressed in arbitrary units (U/mL) with 1 unit
of activity corresponding to approximately 0.8 ng of
purified antigenic protein for CA19-9.

miRNA Extraction and Purification
Pancreatic juice was cleared through centrifugation at 1,300 × g at 4°C for 10 minutes and stored at
-80°C. Total RNA was extracted and purified from all
pancreatic juice samples. For the purpose, cleared
pancreatic juice was mixed with Trizol LS (1:3 ratio;
Life Technologies, Grand Island, NY), and after phase
separation by centrifugation, the aqueous phase was
extracted once with phenol/chloroform and added to
ethanol before being applied directly to a mirVana
miRNA column (Ambion, Austin, TX) according to
the manufacturer’s instructions. The concentration of
RNA samples was quantified using NanoDrop 2000
(NanoDrop, Wilmington, DE). The total amount of
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RNA extracted from 500 µL of pancreatic juice ranged
from 0.21 to 18.90 µg (mean, 1.34 µg).

miRNA Microarray Labeling, Hybridization,
and Data Analysis
The G4470A Agilent human miRNA microarray
(Agilent Technologies, Santa Clara, CA) was used to
profile miRNA. RNA labeling and hybridization were
performed using the Agilent miRNA labeling reagent
and hybridization kit according to the manufacturer’s
protocol. Samples containing 100 ng of RNA were
labeled with pCp-Cy3 using T4 RNA ligase (Ambion)
and hybridized to microarrays. Microarrays were
scanned using an Agilent microarray scanner, data
were extracted, and array quality control was performed using Agilent Feature Extraction software.
The AgiMicroRna package was used to process Agilent miRNA array data. In addition, hierarchical
clustering was performed using Pearson correlation
metrics with Ward’s linkage.

Quantitative Real-Time Polymerase Chain
Reaction (qRT-PCR) Analysis
Taqman miRNA assays (Applied Biosystems,
Foster City, CA) were used to perform expression
profiling of the miRNAs of interest. RNA was pretreated with DNase (Invitrogen). Ten ng of
DNAse-treated RNA from each sample of pancreatic
juice was used for each assay. Assays were performed
in 15-μL reactions containing the reverse transcription
mixture and Taqman primer mix. miRNA expression
levels were quantified using the ViiA™ 7 Real-Time
PCR System (Life Technologies). Relative expression
of the mature miRNAs in terms of fold change in the
test samples (PDAC or CP) compared with the
non-pancreatic, non-healthy (NPNH) controls was
calculated using the comparative CT (2-ΔΔCT) method,
using RNU6B as the endogenous control to normalize
the data, where CT (cycle threshold) is defined as the
number of cycles required for the FAM signal to cross
the threshold in real-time PCR. ΔCT was calculated by
subtracting the CT values of RNU6B from the CT
values of the miRNA of interest. ΔΔCT was then calculated by subtracting the mean ΔCT of NPNH controls from the ΔCT of test samples (PDAC or CP).

Locked Nucleic Acid In Situ Hybridization
(LNA-ISH)
For analyzing miRNA expression formalin-fixed,
paraffin-embedded tumor tissue slides were toasted,
de-waxed in xylenes, and rehydrated through an
ethanol dilution series. Tissue sections were digested
with 15 μg/mL proteinase K and then treated with 3%
hydrogen peroxide. Tissue sections were then subjected to prehybridization solution at 50°C for 30
http://www.jcancer.org
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minutes. The prehybridization solution was replaced
with 50 μL of hybridization solution containing 10
pmol of the fluorescein isothiocyanate–labeled LNA
probes for the miRNAs. Slides were blocked with 5%
bovine serum albumin, incubated with anti-Fluorescein-HRP conjugated antibodies, and subjected to the CSA II Biotin-free Tyramide Signal Amplification System Kit (DAKO, Carpenteria, CA) as
described previously (25).

Statistical Analysis
All clinicopathologic variables and miRNA expression levels in pancreatic juice were analyzed using SPSS v19 (SPSS Inc, Chicago, IL). Unpaired t tests
were used to compare pancreatic juice miRNA expression between groups and p values <0.05 were
considered statistically significant. The relationship
between miRNA expression and overall survival (OS)
was evaluated using Cox proportional hazards reTable 1. Characteristics of the Study Population.
Characteristic

Age, years
<60
61-70
>70
Sex
Male
Female
Ethnicity
White
Black
Hispanic
Asian
Smoking historya
Current
Former
Never
History of alcohol usea
Current
Former
Never
Diabetes mellitusa
Yes
No
CA19-9, U/mL
<50
51-500
501-1500
>1500
Lymph node b
0
1
Tumor differentiationa
Well to moderate
Poor or not
available

NPNH
(n = 19)

CP (n =
19)

PDAC (n = 50)
No. of
No. of
patients
death

MST
(months)

9
6
4

8
5
6

12
18
20

7
15
13

10.73
8.70
4.37

5
14

11
8

30
20

22
13

5.70
10.73

16
2
1
0

17
1
0
1

48
2
0
0

34
1
0
0

8.00
2.07

2
6
11

7
6
6

9
15
25

6
8
21

5.63
8.70
5.20

gression models. Hazard ratios and 95% confidence
intervals (CIs) were calculated, with adjustments
made for sex, ethnicity, and other clinical factors that
were significant predictors of OS in multivariate Cox
regression models. Receiver operating characteristic
(ROC) curves were constructed and the area under
the curve (AUC) was calculated to evaluate the ability
of each individual miRNA and CA19-9 either individually or in combination to detect pancreatic cancer.
OS curves were estimated using the Kaplan-Meier
method. The median expression level of each miRNA
was used as the cutoff point in Kaplan-Meier survival
analysis.

Results
Patient Characteristics
Among the 88 patients enrolled in the study
(training and validation sets), 19 were NPNH controls, 19 were diagnosed with CP, and 50 were
diagnosed with PDAC. Patient demographic
and clinicopathologic information is presented
in Table 1. Among the 50 patients with PDAC,
P
value
univariate analysis by SPSS showed that OS
0.188
did not differ by age, sex, smoking and alcohol
history, diabetes mellitus, CA19-9 findings, or
lymph node involvement. The median OS du0.109
ration of the 50 patients with PDAC was 7.90
months (95% CI, 0.417-41.09 months). However, the median follow-up time was 12.43
0.047
months for the patients who were still alive at
the time of analysis. Well to moderate tumor
differentiation was associated with increased
OS duration (P=0.005).
0.347

0.696
9
5
5

9
5
5

24
8
17

14
7
14

6.77
8.70
10.27
0.451

3
16

5
14

10
39

7
28

3.93
8.70

9
1
3
6

6
1
4
8

6
4
5
35

3
2
4
26

9.77
2.07
2.33
7.90

19
0

19
0

35
13

26
9

8.00
6.77

0.404

0.290

0.005
-

-

9
40

5
30

18.33
5.63

aSmoking history, history of alcohol use, diabetes status and tumor differentiation were not
available for 1 patient with PDAC. b lymph node was not available for 2 patient with PDAC.

Pancreatic Juice miRNA Profiles of
Patients with PDAC
The pancreatic juice miRNA microarray
profiles of 6 patients with PDAC were compared with those of pooled samples from 6
NPNH controls. Hierarchical clustering of
miRNA expression using the Pearson correlation distance metric and Ward’s linkage revealed clusters of patients with PDAC and
NPNH controls after Robust Multi-Array Average (RMA) normalization (Fig. 1A). Levels of
49 miRNAs differed by at least 1.5-fold in the
pancreatic juice of patients with PDAC compared with that of NPNH controls (P < 0.05;
Additional File 1: Supplementary Table S1). To
statistically analyze the similarity of pancreatic
juice miRNA profiles among patients with
PDAC, we generated a dendrogram of cancer-dependent miRNAs, in which PDAC pancreatic juice samples with similar miRNA prohttp://www.jcancer.org
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files were grouped together (Fig. 1B). Multiple miRNAs with elevated profiles in the pancreatic juice,
including miR-205 and miR-210, which are known to
be overexpressed in PDAC tissue (26, 27), were found
to segregate into distinct clusters in the dendrogram
generated. We selected miR-492 and miR-1247, the top
two miRNAs in the same cluster as miR-205 and
miR-210, which have not been previously reported in
PDAC, for validation as novel candidate biomarkers
circulating at elevated levels in the pancreatic juice of
patients with PDAC.

Quantitative Real-Time Polymerase Chain
Reaction (qRT-PCR) Analysis of Candidate
miRNAs
To validate the differential enrichment of four
candidate miRNA biomarkers in pancreatic juice,
identified on expression microarrays, we used
qRT-PCR assay for 4 miRNAs (miR-205, miR-210,
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miR-492, and miR-1247) in individual pancreatic juice
samples (training set). The relative abundance of four
miRNAs, normalized to the level of RNU6B, significantly varied in pancreatic juice samples from patients
with PDAC and NPNH. The levels of four miRNAs
were further assayed in a larger cohort consisting of
an independent set of pancreatic juice samples (validation set). The p values revealed that the levels of
these miRNAs showed statistically significant differences among patients in these three groups (PDAC,
CP and NPNH; miR-205, P = 0.04; miR-210, P =
1.90E-05; miR-492, P = 0.005; miR-1247, P = 0.04; Fig.
2A and Table 2). The mean fold changes of miRNAs
and the p values reflected segregation of PDAC, CP,
and NPNH samples in terms of varying miRNA levels, with the levels relatively high in PDAC, low in
controls and intermediate in CP although the difference between PDAC and CP were not significant.

Figure 1. Hierarchical clustering analysis of microRNA microarray expression profile. (A) Clusters of patients with pancreatic ductal adenocarcinoma (PDAC) and
non-pancreatic, non-healthy controls (NPNH). (B) Hierarchical clustering of microRNA expression in PDAC pancreatic juice samples with similar miRNA profiles were grouped
together, which showed that miR-492, miR-1247, miR-205 and miR-210 were in the same cluster.

http://www.jcancer.org
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Figure 2. Quantitative real-time polymerase chain reaction (qRT-PCR) and Locked nucleic acid in situ hybridization (LNA-ISH) analysis of expression
levels of microRNAs. (A) qRT-PCR analysis of relative expression levels of 4 microRNAs (miR-205, miR-210, miR-492, and miR-1247) in pancreatic juice samples from patients
with pancreatic ductal adenocarcinoma (PDAC), patients with chronic pancreatitis (CP), and non-pancreatic, non-healthy (NPNH) controls. The relative abundance of four
miRNAs, normalized to the level of RNU6B, significantly varied in pancreatic juice samples from patients with PDAC, CP and NPNH. (B) LNA-ISH-IHC images showing miR-492
expression in 3 (J101, J16, J39) pancreatic ductal adenocarcinoma tissue samples (magnification ×100). (C) The graph shows qRT-PCR results for miR-492 in pancreatic juice
samples from the same patients.

Table 2. MicroRNA (miRNA) expression in samples of pancreatic
juice from patients with pancreatic ductal adenocarcinoma
(PDAC); Chronic pancreatitis (CP); Non-pancreatic, non-healthy
controls (NPNH).
miRNA
expression
miR-205
Low
High
miR-210
Low
High
miR-492
Low
High
miR-1247
Low
High
miR-205/
miR-210
0-1
2

NPNH samples
(n = 19), no. (%)

CP samples (n PDAC samples
= 19), no. (%) (n = 50), no. (%)

14 (74)
5 (26)

10 (53)
9 (47)

20 (40)
30 (60)

18 (95)
1 (5)

10 (53)
9 (47)

16 (32)
34 (68)

16 (84)
3 (16)

10 (53)
9 (47)

20 (40)
30 (60)

13 (76)
4 (24)

9 (47)
10 (53)

20 (41)
29 (59)

P value
0.04

1.90E-05

Expression of miRNAs in PDAC Tumor
Samples

0.005

To investigate whether varying levels of miRNAs detected in the pancreatic juice of patients with
PDAC reflected differential expression of the miRNAs
in pancreatic tumor tissues, we performed LNA-ISH
with the miRNA probes on a limited set of 12 available tumor tissue samples. miRNAs detected by
LNA-ISH in the tumor tissues (Fig. 2B) were consistent with those detected in the corresponding pancreatic juice samples (Fig. 2C).
To estimate miRNA-492 and miRNA-1247 differential expression in PDAC, qRT-PCR analysis of
miRNA expression was also undertaken in 34 paired
samples of PDAC tissue and adjacent normal tissue.
Twenty PDAC tumor samples (59%) showed increased expression of miR-492, and only 13 samples
(38%) showed increased expression of miR-1247 (data
not shown).

0.04

8.31E-04
19 (100)
0

13 (68)
6 (32)

miRNAs were higher in the CP samples than in the
NPNH samples, although the difference was statistically significant for only miR-492. Levels of miR-205,
miR-210, and miR-1247 did not differ between the CP
samples and the NPNH samples. These miRNAs were
significantly elevated in PDAC samples compared
with NPNH samples but not compared with the CP
samples.

26 (52)
24 (48)

The relative increase in the levels of the candidate miRNAs in pancreatic juice samples from patients with PDAC was significantly higher than in
samples from NPNH controls (miR-205, P = 0.009;
miR-210, P = 0.010; miR-492, P= 0.003; miR-1247, P=
0.041; Additional File 1: Supplementary Table S2).
These results were in good agreement with microarray and training set results. Levels of the candidate

http://www.jcancer.org
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Pancreatic Juice miRNA Profiles as
Biomarkers of PDAC
The ability of the 4 miRNAs to differentiate
PDAC pancreatic juice samples from NPNH pancreatic juice samples was assessed using ROC curves,
which indicated that the 4 miRNAs are candidate
biomarker of PDAC (miR-205 AUC = 0.68; miR-210
AUC = 0.84; miR-492 AUC = 0.80; miR-1247 AUC =
0.63). For all 4 miRNAs combined, the AUC was 0.92,
documenting that the altered levels of the 4 miRNAs
in pancreatic juice can differentiate patients with
PDAC from NPNH controls. When serum expression
of CA19-9 was considered along with the 4 miRNAs,
the AUC was 0.99, which was significantly improved
compared with both CA19-9 alone (AUC = 0.89) and
the combination of the 4 miRNAs without CA19-9
(Fig. 3A and Additional File 1: Supplementary Table
S3).
ROC curves helped determine the sensitivities
and specificities of the miRNAs at various cutoff values (Supplementary Table S3). Using the optimal
cutoff points, sensitivity and specificity were 64% and
74%, respectively, for miR-205; 76% and 95% for
miR-210; 73% and 82% for miR-492; and 53% and 88%
for miR-1247. The sensitivity and specificity for the 4
miRNAs combined were 87% and 88%, respectively.
Finally, the combination of the 4 miRNAs plus
CA19-9 had a sensitivity of 91% and a specificity of
100%, which was significantly improved than CA 19-9
alone (77% sensitivity, 93% specificity).
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Pancreatic Juice miRNAs as Biomarkers for
PDAC Prognosis, Tumor Differentiation, and
Lymph Node Metastasis
We performed Kaplan-Meier analyses to assess
the relationship between pancreatic juice miRNA levels and clinical outcome, using the median expression
level as a cutoff (at or above the median = high expression; below the median = low expression), in 36
PDAC patients for whom all the clinical data were
available. Multivariate Cox regression models for individual miRNAs and combinations of miRNAs are
shown in Table 3. Patients with low levels of miR-205
or miR-210 (individually) had longer OS durations
than patients with high levels of these miRNAs, but
the difference was not statistically significant
(miR-205 log-rank P = 0.166; miR-210 log-rank P =
0.211). However, we found that elevated levels of all 4
miRNAs was associated with shorter OS (log-rank P =
0.050), as was high expression of both miR-205 and
miR-210 together (log-rank P = 0.029). Patients with
low levels of both miR-205 and miR-210 tended to
have longer OS durations than did patients with high
levels of both miR-205 and miR-210 (Fig. 3B).
Patients with low levels of both miR-205 and
miR-210 appeared less likely to have lymph node
metastasis than patients with high levels of both
miR-205 and miR-210 (Additional File 1: Supplementary Table S4). Patients with low levels of miR-205
also tended to have well to moderately differentiated
tumors (P = 0.001) (Additional File 1: Supplementary
Table S4).

Figure 3. Receiver operating characteristic curves (ROC) and Kaplan-Meier plots showing association of pancreatic juice miRNA profiles in PDAC
patients and their clinical outcome. (A) Receiver operating characteristic curves showing expression levels of individual microRNAs (miR-205, miR-210, miR-492, and
miR-1247), CA19-9, and a combination. (B) Kaplan-Meier overall survival curves for patients with pancreatic ductal adenocarcinoma with high levels of both miR-205 and miR-210
at or above the median (shown in green); either miR-205 or miR-210, or neither upregulated in pancreatic juice samples (shown in blue). The curves were compared using
univariate (log-rank) analysis.
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Table 3. Median overall survival time (MST) of pancreatic ductal
adenocarcinoma (PDAC) patients with high and low levels of
circulating miRNAs in pancreatic juice.
miRNA
expression
miR-205
Low b
High c
miR-210
Low
High
miR-492
Low
High
niR-1247
Low
High
miR-205/miR
-210/
miR-492/miR
-1247
0-3d
4e
miR-205/miR
-210
0-1f
2g

No. of
patients

No. of
deaths

Log-rank P HR (95% CI)a
MST,
months value

P
value

15
21

13
20

12.40
5.63

0.166

1.46(0.66-3.12) 0.347

11
25

9
24

11.33
6.77

0.211

1.78(0.66-4.80) 0.254

17
19

15
18

7.90
8.70

0.678

0.82(0.36-1.83) 0.620

14
21

14
18

6.77
7.90

0.586

1.47(0.67-3.23) 0.334

32
4

29
4

8.70
3.77

0.050

2.87 (0.93-8.87) 0.067

18
18

15
18

11.33
3.93

0.029

2.14 (1.06-4.29) 0.030

Hazard ratios (HR) derived from multivariate Cox regression models adjusted for
sex, ethnicity, CA19-9 levels, and stage;
bLow < the median expression level; cHigh ≥ the median expression level; d0-3:
Patients with ≤ three miRNAs (miR-205, miR-210, miR-492 and miR-1247) upregulated in pancreatic juice; e4: Patients with four miRNAs upregulated in pancreatic
juice; f0-1: Patients with either miR-205 or miR-210 upregulated in pancreatic juice;
g2: Both miR-205 and miR-210 upregulated in pancreatic juice of the same patient.
a

Discussion
Elevated levels of microRNAs have been detected in precursor lesions of pancreatic cancer and
were also associated with poorer survival of pancreatic cancer patients (26, 27). Our results indicate that
miR-205, miR-210, miR-492, and miR-1247 in pancreatic juice are candidate biomarkers of PDAC, which
perform even better when combined with serum
CA19-9 levels. We also found that expression of these
4 miRNAs is associated with decreased OS in patients
with PDAC. In addition, elevated amount of miR-205
and miR-210 was associated with lymph node metastasis, and expression of miR-205 was associated with
poorly differentiated tumors, both indicators of worse
prognosis. These findings suggest that pancreatic
juice levels of miR-205, miR-210, miR-492, and
miR-1247, as a combined signature can predict the
clinical outcome of patients with PDAC.
Microarray analyses identified 49 miRNAs as
differentially enriched in the pancreatic juice of patients with PDAC compared with controls; of these,
miR-200a, miR-200b, and miR-30b have also been
found to be upregulated in PDAC cells and tumor
tissue (28). In addition, high expression of miR-205
was found in head and neck cancer cell lines (29),
squamous cell carcinoma cell lines (30), and cervical

cancer cell lines (31), as well as in clinical samples of
metastatic head and neck squamous cell carcinoma
(32), cervical cancer (31), non-small cell lung cancer
(33), and endometrial cancer (34). Expression of
miR-205 in clinical prostate cancer samples was associated with prostate cancer progression (35) and invasive bladder cancers (36). Up-regulation of miR-205
was also found to precede phenotypic changes in
ductal cells in a conditional KRAS (G12D) mouse
model of pancreatic cancer (27).
Aberrant high expression of miR-210 has been
detected in many tumors (26, 37-42)., Elevated
miR-210 has been implicated in tumor progression
(43) and is associated with negative clinical outcomes
(26, 41, 42). Interestingly, increased plasma miR-210
levels were associated with lymph node metastases
and trastuzumab resistance in breast cancer patients
(44). These findings are to some extent consistent with
our current observation that high miR-205 and
miR-210 levels in pancreatic juice correlate with decreased OS, poorly differentiated tumors, and lymph
node metastasis. These observations make a compelling case for miR-205 and miR-210 in pancreatic juice
as informative biomarkers for PDAC.
A recent study has reported miR-1247 to be
down-regulated in pancreatic cancer correlating with
tumor grade and shorter overall survival of the patients (45). miR-492 has also been shown to potentially
play an important role in the progression of malignant
embryonal liver tumors (46). Although our study did
not reveal significant differences in the levels of these
miRNAs between CP and PDAC, it is plausible that
this was due to relatively small sample size and thus
lack of enough statistical power in the current study.
However, in view of these miRNAs discriminating
PDAC from NPNH controls with reasonably high
sensitivity and specificity as well as showing significant correlation with decreased OS and lymph node
metastasis, it is important that the miRNA signature
be investigated in a larger patient population in the
future. The current finding of the four miRNAs signature in pancreatic juice as a biomarker panel of
pancreatic cancer suggest that these miRNAs are involved in critical cancer relevant genetic networks
deregulated in PDAC.
Collection of pancreatic juice is a minimally invasive procedure which can easily detect circulating
or secreted miRNAs as concentrations of miRNAs are
higher than in blood (serum or plasma). This is important as circulating miRNAs in blood can potentially decrease over time whereas they can be still detectable in pancreatic juice. For detection of early
PDAC, this procedure will be preferable as concentrations of miRNAs will be higher in pancreatic juice
than in blood. Moreover, our technique can be used as
http://www.jcancer.org
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part of routine diagnostic procedure to establish diagnosis/staging of PDAC and does not involve cannulation of pancreatic duct to collect pancreatic juice.
Finally, we recognize that the procedure is expensive if secretin is used and more invasive unlike
detecting miRNAs in blood., The collection and storage procedures need to be standardized for a broader
applicability of this technique. It is important to have
stringent quality control standards for collection of
pancreatic juice and pancreatic juice miRNAs expression analysis besides ensuring that sample size is adequate for selecting the most informative candidate
biomarker miRNAs capable of discriminating patients
with pancreatic cancer, pancreatitis versus no pancreatic disease.
In summary, our study demonstrates that
miRNAs in exocrine pancreatic secretions are promising biomarkers of PDAC. Further comprehensive
molecular and functional characterizations of miRNAs circulating at altered levels in pancreatic juice are
warranted to elucidate the role of these miRNAs in
pancreatic carcinogenesis and validate them in larger
sample cohorts as biomarker panels for detection,
prognosis as well as response to therapy for this
highly lethal malignancy.
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